Introduction {#Sec1}
============

Osteoporosis is characterized by reduced bone mineral density (BMD), increased microstructural deterioration, and, consequently, increased fracture risk. Worldwide, approximately 9 million new osteoporotic fractures occur per year, including 1.7 million fractures of the forearm, 1.6 million fractures of the hip, and 1.4 million clinical vertebral fractures \[[@CR1]\]. Wrist fractures are the most common nonvertebral fractures in postmenopausal women with osteoporosis, particularly in elderly women \[[@CR2]--[@CR5]\]. Individuals with wrist fractures may experience chronic loss of function \[[@CR6]\] and reduced quality of life \[[@CR5]\]. Furthermore, wrist fractures are associated with significant morbidity \[[@CR2]--[@CR4]\] and may be associated with increased mortality, especially in men \[[@CR7], [@CR8]\]. Forearm, wrist, and humerus fractures have also been shown to predict subsequent vertebral, hip, wrist, and forearm fractures \[[@CR9]--[@CR13]\].

Data on currently available therapies are limited with regard to treatment effects on wrist fractures and corresponding changes in BMD. Studies of alendronate have shown both significant \[[@CR14]\] and nonsignificant \[[@CR15]\] reductions in wrist fractures compared with placebo. Studies have also shown that bisphosphonates maintain reductions in BMD at the distal radius compared with baseline, especially at the 1/3 radius, which is primarily cortical bone \[[@CR16]--[@CR19]\]. Studies of teriparatide have shown both significant decreases in wrist fractures \[[@CR20]\] and significant reductions in wrist BMD \[[@CR21]\] compared with placebo. Thus, previous reports of osteoporosis medications do not present a clear association between changes in BMD and fracture risk at the wrist.

In contrast to other antiresorptive therapies, denosumab---a fully human monoclonal antibody against RANK ligand (RANKL)---increases BMD at the 1/3 radius, as determined by dual-energy X-ray absorptiometry (DXA), more than alendronate not only in bisphosphonate treatment-naïve patients \[[@CR22]\] but also in previously bisphosphonate-treated patients \[[@CR23]\]. Denosumab also enhances BMD at the 1/3 radius more than zoledronic acid in patients previously treated with long-term alendronate \[[@CR24]\]. In a phase 2 study, denosumab reduced bone resorption more rapidly and decreased cortical porosity more than alendronate \[[@CR17]\].

While denosumab was not shown to reduce wrist fractures in the overall study population of the FREEDOM study \[[@CR25], [@CR26]\], improvements in bone mass, density, and strength \[[@CR18]\] with denosumab treatment have been associated with reductions in wrist fractures among women at higher risk, defined as having a femoral neck BMD T-score ≤ − 2.5 \[[@CR26]\]. Long-term experience with denosumab provides further support for the relationship between increases in BMD and reductions in nonvertebral fracture risk \[[@CR27], [@CR28]\].

No study has assessed the effect of treatment on long-term (\> 3 years) forearm BMD changes and the risk of upper limb fractures (i.e., wrist, forearm, and humerus). With this objective, we evaluated the long-term effects of denosumab treatment on changes in forearm BMD by DXA and their relationship with fracture incidence at three different upper limb sites. We used data from the cross-over group of subjects from the FREEDOM Extension trial, who received 3 years of placebo followed by up to 7 years of denosumab. The results provide further evidence for the beneficial effects of denosumab at both cortical and trabecular compartments of the bone, leading to reductions in the risk of upper limb fractures.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

The 3-year FREEDOM trial (NCT00089791) and its 7-year Extension (NCT00523341) have been described previously \[[@CR25], [@CR28]\]. Briefly, FREEDOM was a phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of denosumab in postmenopausal women with osteoporosis. Subjects were randomized to receive either placebo or denosumab 60 mg subcutaneously (SC) every 6 months (Q6M) for 3 years. Subjects were instructed to take calcium (≥ 1 g) and vitamin D (≥ 400 IU) daily. Subjects who completed the FREEDOM trial, did not discontinue investigational product, and did not miss \> 1 dose of investigational product were eligible to enter a 7-year Extension trial. During the Extension, all subjects were to receive open-label denosumab 60 mg SC Q6M, with daily calcium and vitamin D.

This analysis evaluated subjects who were randomized to receive placebo for 3 years in the FREEDOM, entered the Extension study, and received denosumab for up to 7 years (i.e., the cross-over group). The cross-over group was chosen because it provided fracture rates during the placebo period, which was used for within-group comparisons. Fracture rates at the wrist, forearm, humerus, and all upper limb fractures together were assessed in all subjects from the cross-over group. A subset of subjects from the cross-over group also participated in a BMD substudy, in which forearm BMD was measured. This substudy was prespecified in both the FREEDOM and Extension trial protocols.

Study population {#Sec4}
----------------

Subjects who were randomized to placebo in the FREEDOM and received up to 7 years of denosumab in the Extension were included in this analysis. Subject inclusion and exclusion criteria have been described previously \[[@CR28]\]. Women between the age of 60 and 90 years with a lumbar spine or total hip BMD T-score ≤ − 2.5 at either site but \> − 4.0 at both sites were eligible for the FREEDOM trial.

Outcome measures {#Sec5}
----------------

BMD assessments were performed by DXA. DXA measurements were obtained by Lunar or Hologic instruments (GE Healthcare, Chicago, IL, or Hologic Inc., Marlborough, MA, respectively). All DXA scans were analyzed centrally by Synarc (Portland, OR) in a blinded fashion. During the 10-year course of FREEDOM and its Extension, the central laboratory made appropriate adjustments upon each change in software to ensure consistency of BMD results. Ultradistal radius, 1/3 radius, and total radius DXA measurements were recorded for a subset of subjects at FREEDOM baseline, during FREEDOM (years 1--3), and during FREEDOM Extension (years 1--3, 5, and 7). Wrist, forearm, humerus, and upper limb (combined wrist, forearm, and humerus) fracture rates were confirmed by a central imaging vendor for all subjects through year 3 in the FREEDOM study and through year 7 of FREEDOM Extension. Fractures of interest by site were defined in the following manner: wrist fractures included fractures at the distal radius and distal ulna; forearm fractures included fractures at the proximal radius/ulna, shaft radius/ulna, and distal radius/ulna; humerus fractures included fractures at the proximal humerus, shaft humerus, and distal humerus; and upper limb fractures included fractures at the forearm and humerus. Traumatic and pathologic fractures were excluded. Changes in BMD and fracture rates were evaluated in three time periods to allow for within-group comparisons---FREEDOM years 1--3, Extension years 1--3, and Extension years 4--7---to evaluate patients after they received 3 years of placebo, 3 years of denosumab, and 4 additional years of denosumab, respectively. Fracture rates were compared between either the first 3 years on denosumab or the subsequent last 4 years on denosumab with the first 3 years on placebo to assess the effect of denosumab treatment on fracture rates. To adjust for various lengths of follow-up, fracture rates were expressed as per 100 subject-years. Rate ratios were used for within-group comparison between placebo and denosumab treatment periods. Fracture rates and changes in BMD are also reported for the long-term group (i.e., subjects randomized to receive denosumab during FREEDOM, entered the Extension, and received denosumab for up to an additional 7 years), to compare with those observed in the cross-over group during the same period of denosumab treatment in the Extension (i.e., the first 3 years and following 4 years of denosumab treatment).

Statistical analyses {#Sec6}
--------------------

Baseline demographic and disease characteristic values were summarized using descriptive statistics. The percentage change from FREEDOM baseline and Extension baseline in BMD at the ultradistal radius, 1/3 radius, and total radius by visit (during the FREEDOM and its Extension) was analyzed using a repeated-measures mixed-effects model with an unstructured within-subject variance-covariance structure. The model included treatment, visit (categorical), baseline BMD value, age stratification variable, densitometry machine type, treatment-by-visit interaction, and BMD baseline value-by-densitometry machine-type interaction. Least squares mean estimates of the percentage change from baseline in BMD within each treatment group and by visit, and the corresponding two-sided 95% confidence intervals (CIs), were estimated. Wrist, forearm, humerus, and upper limb fracture rates (per 100 subject-years) were computed, and the rate ratios (comparing FREEDOM Extension years 1--3 or 4--7 with placebo FREEDOM years 1--3 and comparing FREEDOM Extension years 4--7 with FREEDOM Extension years 1--3) and the corresponding 95% CIs were estimated by generalized estimating equation method in a Poisson regression model. All *p* values were not adjusted for multiplicity.

Results {#Sec7}
=======

Subjects {#Sec8}
--------

Of the 3906 subjects randomized to placebo in FREEDOM, 2207 entered the FREEDOM Extension. The FREEDOM BMD substudy enrolled 441 subjects (209 placebo and 232 denosumab) at FREEDOM baseline; results from the FREEDOM substudy have previously been published \[[@CR29]\]. Among the 209 placebo subjects in the FREEDOM BMD substudy, 116 enrolled in the Extension and had at least one 1/3 radius BMD measurement at baseline or postbaseline in the Extension. Baseline characteristics for FREEDOM and FREEDOM Extension subjects who entered FREEDOM Extension and those who participated in the BMD substudy are shown in Table [1](#Tab1){ref-type="table"}. At the beginning of the FREEDOM trial, subjects had a mean age of 72 years, 28% of the subjects were over the age of 75 years, and 22% had a prevalent vertebral fracture. Within the BMD substudy at FREEDOM baseline, mean age was 72 years, 34% of the subjects were over the age of 75 years, 21% had a prevalent vertebral fracture, and mean (standard deviation) BMD T-score was − 2.5 at the 1/3 radius and − 2.5 at the ultradistal radius.Table 1FREEDOM and Extension baseline characteristicsCharacteristicCross-over Extension subjectsFREEDOM baselineExtension baselineOverall *N* = 2207Substudy *N*1 = 116Overall *N* = 2207Substudy *N*1 = 116Age (years)71.8 (5.1)72.2 (5.2)74.8 (5.1)75.2 (5.2)Age groups (%)  ≥ 65 years93.794.097.496.6  ≥ 75 years28.333.652.256.0Time since menopause (years)23.7 (7.4)24.3 (8.4)26.7 (7.4)27.3 (8.4)BMI (kg/m^2^)26.0 (4.1)24.9 (4.3)25.9 (4.2)25.0 (4.4)Height (cm)157.0 (6.9)157.7 (6.7)157.0 (6.9)157.7 (6.7)Weight (kg)64.0 (10.3)62.0 (10.5)63.7 (10.7)62.3 (10.9)Prevalent vertebral fracture (%)22.020.725.024.1Prevalent nonvertebral fracture at age ≥ 55 years (%)29.527.634.231.0Lumbar spine BMD T-score− 2.84 (0.68)− 2.81 (0.61)− 2.81 (0.75)− 2.80 (0.66)Total hip BMD T-score− 1.85 (0.79)− 1.85 (0.64)− 1.93 (0.80)− 1.92 (0.63)1/3 radius BMD T-score^a^N/A− 2.53 (1.18)N/A− 2.66 (1.13)Ultradistal radius BMD T-score^a^N/A− 2.47 (1.02)N/A− 2.65 (1.04)sCTx,^b^ ng/mL, median (Q1, Q3)0.56 (0.42, 0.66)0.53 (0.37, 0.61)0.57 (0.43, 0.73)0.45 (0.36, 0.60)P1NP,^b^ μg/L, median (Q1, Q3)55.81 (42.52, 65.60)47.02 (43.00, 67.88)48.80 (35.04, 67.58)50.65 (36.49, 59.99)Serum 25-hyrdoxyvitamin D,^c^ ng/mL24.29 (34.78)22.34 (8.11)N/AN/A*N* = 2207 was defined as the number of subjects randomized to placebo in the FREEDOM and enrolled in the Extension*N*1 = 116 was defined as the number of subjects enrolled in the Extension DXA substudy with the FREEDOM baseline and at least one postbaseline 1/3 radius BMD measurement in the FREEDOM or the ExtensionData are mean (standard deviation) unless otherwise noted*BMD*, bone mineral density; *BMI*, body mass index; *BTM*, bone turnover marker; *DXA*, dual-energy x-ray absorptiometry; *N/A*, not applicable; *P1NP*, procollagen type 1 N-terminal propeptide; *Q*, quartile; *sCTx*, serum C-telopeptide of type 1 collagen^a^BMD measurements at the 1/3 radius and ultradistal radius were performed in a subset of subjects enrolled in the DXA substudy^b^BTM subsets include subjects who enrolled in the BTM substudy^c^Serum 25-hydroxyvitamin D was only assessed in the FREEDOM

Baseline characteristics were similar between the overall population and the substudy population. Between the FREEDOM and Extension trials, baseline characteristics were similar except that subjects were 3 years older and had 3 years longer since menopause; the percentage of subjects aged over 75 years and those with prevalent vertebral and nonvertebral fractures was, as expected, greater, and T-scores (total hip, 1/3 radius, and ultradistal radius) were lower.

Upper limb fractures {#Sec9}
--------------------

The overall rate of upper limb fractures, including the wrist, forearm, and humerus, decreased over the 7-year course of treatment with denosumab (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Wrist, forearm, humerus, and all upper limb fracture rate*.* Fracture incidence (95% CI) per 100 subject-years at the **a** wrist, **b** forearm, **c** humerus, and **d** all upper limb. 95% CIs were estimated by generalized estimating equation (GEE) method in a Poisson regression model. All *p* values were not adjusted for multiplicity. CI, confidence interval

The incidence of wrist fractures was 1.02 per 100 subject-years during FREEDOM years 1--3 (during which all subjects received placebo) and 0.96 during Extension years 1--3 (during which all subjects received denosumab; rate ratio not significant), and decreased to 0.58 during Extension years 4--7 (rate ratio (95% CI) = 0.57 (0.38--0.86); *p* = 0.0077, Extension years 4--7 vs FREEDOM years 1--3; Fig. [1a](#Fig1){ref-type="fig"}).

Within these same periods, the rate of forearm fractures was 1.14 per 100 subject-years during FREEDOM years 1--3 and 1.03 during Extension years 1--3 (rate ratio not significant), and decreased to 0.65 during Extension years 4--7 (rate ratio (95% CI) = 0.57 (0.39--0.84); *p* = 0.0042, Extension years 4--7 vs FREEDOM years 1--3; Fig. [1b](#Fig1){ref-type="fig"}).

The incidence of humerus fractures decreased from 0.44 per 100 subject-years during FREEDOM years 1--3 to 0.20 during Extension years 1--3 (rate ratio (95% CI) = 0.45 (0.23--0.89); *p* = 0.0214, Extension years 1--3 vs FREEDOM years 1--3; Fig. [1c](#Fig1){ref-type="fig"}), and to 0.18 during Extension years 4--7 (rate ratio (95% CI) = 0.42 (0.21--0.83); *p* = 0.013, Extension years 4--7 vs FREEDOM years 1--3; Fig. [1c](#Fig1){ref-type="fig"}).

The fracture rate of the entire upper limb per 100 subject-years was 1.56 during FREEDOM years 1--3 and 1.23 during Extension years 1--3 (rate ratio not significant), and decreased to 0.81 during Extension years 4--7 (rate ratio (95% CI) = 0.52 (0.37--0.72); *p* = 0.0001, Extension years 4--7 vs FREEDOM years 1--3; Fig. [1d](#Fig1){ref-type="fig"}).

For comparison, the fracture rates (95% CI) per 100 subject-years in the long-term group during Extension years 1--3 (i.e., years 4--6 of denosumab treatment) were 0.62 (0.46--0.86) at the wrist, 0.66 (0.48--0.89) at the forearm, 0.12 (0.06--0.25) at the humerus, and 0.78 (0.59--1.03) in the entire upper limb, comparable to those observed in the cross-over group during the same period of denosumab treatment. With 4 additional years of denosumab treatment during Extension years 4--7 (i.e., years 7--10 of denosumab treatment), fracture rates (95% CI) per 100 subject-years were 0.49 (0.34--0.69), 0.54 (0.38--0.75), 0.06 (0.02--0.17), and 0.60 (0.44--0.82), respectively.

Bone mineral density {#Sec10}
--------------------

At the end of FREEDOM year 3, when all subjects had received placebo, BMD at the ultradistal radius, 1/3 radius, and total radius decreased from baseline by 2.1%, 1.2%, and 1.9%, respectively (Table [2](#Tab2){ref-type="table"} and Fig. [2](#Fig2){ref-type="fig"}). During the 7-year Extension study, when all subjects received denosumab, BMD increased significantly from Extension baseline at all sites and all time points observed---ultradistal radius, 1/3 radius, and total radius---with the exception of the 1/3 radius at year 1 (*p* = 0.2308) and year 2 (*p* = 0.5141; Table [2](#Tab2){ref-type="table"}), restoring the BMD that was lost during the FREEDOM study when patients received placebo. The time course of denosumab-associated change in total radius BMD from baseline mimicked that at the 1/3 radius site. The increases in BMD were more pronounced at the ultradistal radius than at either the 1/3 radius or total radius. For comparison, in the long-term group, BMD was maintained or continued to increase with 4 additional years of denosumab treatment (i.e., during Extension years 4--7 or years 7--10 of denosumab treatment) (data not shown).Table 2Percentage change in bone mineral density from the FREEDOM and Extension baselinesYearFrom FREEDOM baselineFrom Extension baseline*n*LS mean (95% CI)*p* value*n*LS mean (95% CI)*p* valuea. Ultradistal radiusFREEDOM (placebo)  Year 1113− 0.4 (− 1.3, 0.6)0.4457N/AN/AN/A  Year 2109− 0.9 (− 1.9, 0.1)0.0633N/AN/AN/A  Year 3111− 2.1 (− 3.5, − 0.8)0.0014N/AN/AN/AExtension (denosumab)  Year 11130.6 (− 1.1, 2.4)0.45411142.9 (1.2, 4.5)0.0008  Year 21070.6 (− 1.3, 2.4)0.53711082.8 (1.1, 4.5)0.0015  Year 3731.2 (− 0.6, 3.0)0.2055733.5 (1.7, 5.3)0.0001  Year 5592.2 (0.4, 4.0)0.0195594.5 (2.8, 6.2)\< 0.0001  Year 7390.7 (− 1.3, 2.7)0.4963393.2 (1.2, 5.3)0.0025b. 1/3 radiusFREEDOM (placebo)  Year 1113− 0.1 (− 0.6, 0.5)0.7807N/AN/AN/A  Year 2109− 0.7 (− 1.42, − 0.1)0.0275N/AN/AN/A  Year 3111− 1.2 (− 1.9, − 0.4)0.0024N/AN/AN/AExtension (denosumab)  Year 1113− 1.0 (− 1.7, − 0.3)0.00721140.3 (− 0.2, 0.9)0.2308  Year 2107− 1.2 (− 1.9, − 0.4)0.00331080.2 (− 0.4, 0.9)0.5141  Year 373− 0.2 (− 1.1, 0.7)0.6519731.3 (0.5, 2.0)0.0011  Year 5590.3 (− 0.7, 1.3)0.5451591.8 (0.9, 2.7)0.0001  Year 7390.6 (− 0.8, 2.1)0.3974392.2 (0.9, 3.6)0.0017c. Total radiusFREEDOM (placebo)  Year 1113− 0.4 (− 1.0, 0.2)0.1534N/AN/AN/A  Year 2109− 1.2 (− 1.8, − 0.5)0.0003N/AN/AN/A  Year 3111− 1.9 (− 2.6, − 1.2)\< 0.0001N/AN/AN/AExtension (denosumab)  Year 1113− 1.0 (− 1.7, − 0.2)0.01391141.2 (0.7, 1.8)\< 0.0001  Year 2107− 1.2 (− 2.0, − 0.3)0.00761081.1 (0.4, 1.7)0.0012  Year 373− 0.3 (− 1.2, 0.5)0.4608732.0 (1.3, 2.8)\< 0.0001  Year 5590.1 (− 0.8, 1.1)0.7928592.5 (1.7, 3.4)\< 0.0001  Year 739− 0.4 (− 1.7, 0.9)0.5693392.1 (0.9, 3.3)0.0009*n* = number of subjects with observed dataBased on a repeated-measures mixed-effects model adjusted for treatment, age stratification variable, visit, baseline value, machine type, treatment-by-visit interaction, and baseline value-by-densitometry machine-type interaction*CI*, confidence interval; *LS*, least squares; *N/A*, not applicableFig. 2Percentage change in ultradistal radius, 1/3 radius, and total radius BMD from FREEDOM baseline. *n* = number of subjects with observed data. Percentage change based on a repeated-measures mixed-effects model adjusted for treatment, age stratification variable, visit, baseline BMD value, machine type, treatment-by-visit interaction, and baseline value-by-machine-type interaction. \**p* \< 0.05 vs FREEDOM baseline. BMD, bone mineral density; BTM, bone turnover marker; CI, confidence interval; DXA, dual-energy x-ray absorptiometry; Q6M, every 6 months

Discussion {#Sec11}
==========

The objective of this study was to evaluate the long-term treatment effect of denosumab on fracture risk of the upper limb and the associated changes in BMD at the forearm, including ultradistal radius, 1/3 radius, and total radius sites. During FREEDOM Extension, long-term denosumab treatment significantly decreased the risk of upper limb fractures, including wrist, forearm, and humerus, which was associated with a complete reversal of bone loss observed during the first 3 years of FREEDOM, when these patients received only calcium and vitamin D supplementation.

Upper limb fractures account for about one-third of all osteoporosis-related fractures in the elderly and are associated with significant morbidity and mortality \[[@CR4], [@CR8]\] and loss of quality of life \[[@CR5]\]. The present study is the first to examine the long-term effect of osteoporosis treatment on upper limb fractures, indicating that 7 years of denosumab treatment was associated with a significant 48% reduction in the risk of all upper limb fractures and a 43%, 43%, and 58% reduction in risk of forearm, wrist, and humerus fractures, respectively, compared with placebo treatment during FREEDOM. Fracture risk reduction with denosumab, however, was not evident during the first 3 years of treatment during the Extension but rather during the last 4 years of treatment, with the exception of the humerus, where a 55% reduction was observed within the first 3 years of denosumab treatment and sustained through 7 years of treatment. It is unclear why the humerus appears to respond earlier to denosumab treatment than the wrist and forearm. While findings from the FREEDOM study demonstrated a significant reduction in nonvertebral fractures with 3 years of denosumab treatment compared with placebo \[[@CR25]\], this current longitudinal analysis suggests that reduction of upper limb fractures may require more than 3 years of therapy because cortical bone is relatively slow to react to an antiresorptive, particularly at a relatively low load site with little---if any---modeling-based bone formation \[[@CR30]\]. It should be mentioned that by the end of the 7-year Extension period, patients were older and, thus, at higher fracture risk compared with the first 3 years of FREEDOM, potentially underestimating the fracture risk reduction observed with denosumab treatment in this longitudinal study without a parallel comparator arm. Our findings indicate that denosumab effectively reduces fractures in the upper limb, including the wrist and humerus, with important clinical implications. Recent recommendations from the National Bone Health Alliance expanded the diagnosis of osteoporosis to include fractures at the proximal humerus and, in some cases, distal forearm in patients with osteopenic BMD \[[@CR31]\].

Although some studies have shown a reduction in wrist fractures with alendronate treatment \[[@CR14], [@CR32]\], others have shown neither a reduction in wrist fractures nor an increase in wrist BMD \[[@CR15], [@CR19]\]. A Cochrane review showed an overall relative risk reduction of about 50% for wrist fractures with alendronate treatment \[[@CR33]\]. No studies have reported the effect of antiresorptive agents on other upper limb fractures.

Among available osteoporosis therapies, reduction in vertebral fracture risk is a consistent finding that becomes evident relatively early in the course of treatment. In addition, the size of the treatment effect on vertebral fractures is greater than that on nonvertebral fractures. Reductions in nonvertebral fractures, including at the upper extremities, are less pronounced with antiresorptive therapies and appear to require a longer treatment duration. Treatment with denosumab results in reductions in vertebral fractures after 1 year, whereas reductions in nonvertebral fractures occur after 3 years. Longer term denosumab treatment beyond 3 years has been shown to be associated with further reductions in nonvertebral fractures \[[@CR27]\]. This long-term, beneficial treatment effect is thought to be derived not only from the increase in bone mass but also from reductions in cortical porosity and increases in cortical thickness and strength documented at nonvertebral sites, including the distal radius, tibia, and hip \[[@CR17], [@CR34]\].

In contrast, longer treatment with alendronate for up to 10 years \[[@CR35]\] or zoledronic acid for up to 9 years \[[@CR36]\] was not associated with further reductions in nonvertebral fractures compared with the first 3 years of each respective treatment. This may be explained by the differing effects of denosumab and alendronate on cortical bone \[[@CR17]\], as well as the differing effects on femoral neck BMD that plateaus after 2--3 years of treatment with bisphosphonates. To inhibit resorption, bisphosphonates must first be adsorbed to hydroxyapatite bone mineral surfaces---more abundantly expressed on trabecular bone than cortical---underneath the osteoclasts, and then later be taken up by osteoclasts during resorption \[[@CR16]\]. Thus, some resorption must occur before bisphosphonates can inhibit osteoclastic activity. Furthermore, bisphosphonates do not prevent osteoclastogenesis. By contrast, denosumab, a fully human monoclonal antibody against RANKL that does not require binding to bone mineral surfaces, reduces osteoclastogenesis and bone resorption more completely and rapidly than bisphosphonates and may penetrate deeper into cortical bone \[[@CR16]\]. These differences in mechanisms of action may confer larger effects of denosumab compared with alendronate on cortical bone \[[@CR17]\].

The strength of this study is that it reports long-term, 10-year changes in BMD at three sites of interest at the radius. The fracture risk reduction calculations were based on a large sample size, i.e., all subjects randomized to placebo in the FREEDOM trial who entered the Extension. In addition, the 7 years of denosumab treatment in the cross-over group could be compared with the first 7 years of denosumab treatment in the long-term group; those findings show similar outcomes, demonstrating that longer term denosumab treatment (beyond 3 years) further decreases fracture risk. The limitation of this study is the relatively small number of subjects who participated in the BMD substudy; however, as baseline characteristics were similar between the subjects enrolled in the overall cross-over group and in the BMD substudy, the subjects investigated appear to be representative of the overall study population. DXA does not measure humeral BMD, so it is not possible to associate reductions in humerus fracture rates with increases in BMD at that skeletal site. This study is also limited by the open-label, single-arm design of the Extension trial and the lack of a placebo group.

In conclusion, compared with the initial 3 years of treatment with calcium and vitamin D supplements during the FREEDOM trial, 7 years of denosumab treatment decreased the incidence of upper limb fractures, including those at the wrist, humerus, and forearm. The beneficial effect of denosumab treatment on fractures was associated with significant increases in BMD over the 7-year course of therapy compared with Extension baseline and complete reversal of the bone loss observed during the first 3 years of the FREEDOM trial. This study also suggests that for some nonvertebral skeletal sites, such as the upper limb, a treatment duration of more than 3 years results in significant and clinically meaningful treatment effect. Considering the reversibility of denosumab, as well as its long-term safety and proven efficacy, continued treatment with a drug holiday is a very important consideration. These findings support the treatment benefits of long-term therapy with potent antiresorptive agents, such as denosumab, and their importance in enabling a patient to maintain one's independence, activity level, and overall quality of life.
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